CN110612098B - 含有伯鲁酶的口腔分散片和由此生产的药物组合物 - Google Patents

含有伯鲁酶的口腔分散片和由此生产的药物组合物 Download PDF

Info

Publication number
CN110612098B
CN110612098B CN201880019225.8A CN201880019225A CN110612098B CN 110612098 B CN110612098 B CN 110612098B CN 201880019225 A CN201880019225 A CN 201880019225A CN 110612098 B CN110612098 B CN 110612098B
Authority
CN
China
Prior art keywords
beryllase
orodispersible
orodispersible tablets
tablets according
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880019225.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN110612098A (zh
Inventor
R·福赫勒
J·吕德曼
L·加勒特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Normark Pharmaceutical Co ltd
Original Assignee
Normark Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Normark Pharmaceutical Co ltd filed Critical Normark Pharmaceutical Co ltd
Publication of CN110612098A publication Critical patent/CN110612098A/zh
Application granted granted Critical
Publication of CN110612098B publication Critical patent/CN110612098B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2068Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003Triacylglycerol lipase (3.1.1.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Non-Alcoholic Beverages (AREA)
CN201880019225.8A 2017-03-03 2018-03-05 含有伯鲁酶的口腔分散片和由此生产的药物组合物 Active CN110612098B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102017104472.8 2017-03-03
DE102017104472.8A DE102017104472A1 (de) 2017-03-03 2017-03-03 Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung
PCT/EP2018/055285 WO2018158459A1 (de) 2017-03-03 2018-03-05 Schmelztablette enthaltend burlulipase und daraus hergestellte pharmazeutische zusammensetzung

Publications (2)

Publication Number Publication Date
CN110612098A CN110612098A (zh) 2019-12-24
CN110612098B true CN110612098B (zh) 2022-05-13

Family

ID=61628314

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880019225.8A Active CN110612098B (zh) 2017-03-03 2018-03-05 含有伯鲁酶的口腔分散片和由此生产的药物组合物

Country Status (9)

Country Link
US (1) US11464834B2 (enExample)
EP (1) EP3525769B1 (enExample)
JP (2) JP7208146B2 (enExample)
CN (1) CN110612098B (enExample)
CA (1) CA3055116C (enExample)
DE (1) DE102017104472A1 (enExample)
ES (1) ES2880602T3 (enExample)
PL (1) PL3525769T3 (enExample)
WO (1) WO2018158459A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017104480A1 (de) * 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Wässrige Lösung von Burlulipase umfassend Kalziumionen
JP2023543710A (ja) * 2020-09-17 2023-10-18 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 流動特性を改善するための、高分子量魚ゼラチンに基づく投薬製剤を伴う、界面活性剤の使用
WO2022103634A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Improved use of cannabinoids in the treatment of epilepsy
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
DE102023200788A1 (de) 2023-01-31 2024-08-01 Technische Universität Braunschweig - Körperschaft des öffentlichen Rechts Festes Lyophilisat und Verfahren zur Herstellung

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1394607A (zh) * 2002-08-07 2003-02-05 王登之 治疗心绞痛的黄杨宁口腔崩解片及其制备方法
CN101068565A (zh) * 2004-10-14 2007-11-07 阿尔特斯制药公司 治疗胰腺功能不全的包含脂酶、蛋白酶和淀粉酶的组合物
DE102009006594A1 (de) * 2009-01-29 2010-08-05 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutisches Präparat
CN102231988A (zh) * 2009-01-29 2011-11-02 诺尔玛克药物有限责任及股份两合公司 细菌脂肪酶药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1642654C3 (de) 1968-01-16 1979-11-29 Centre Europeen De Recherches Mauvernay, C.E.R.M., Riom Verfahren zur mikrobiologischen Herstellung eines stabilen gereinigten Lipase-Präparates und pharmazeutisches Mittel, welches dieses enthält
DE2638088C3 (de) 1976-08-24 1979-06-21 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Verwendung von SuBmolkenpulver
DE69004301T2 (de) 1989-03-08 1994-03-24 Simon Lodewijk Scharpe Mischung zur Behandlung der von exokrinen Insuffizienz der Bauchspeicheldrüse und die Verwendung der genannten Mischung.
JP3593550B2 (ja) 1991-07-01 2004-11-24 ノルトマルク アルツナイミッテル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト 医薬品製造のためのリパーゼの使用
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
WO2000078292A1 (en) 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Quickly disintegrating solid preparations
US6588180B2 (en) 2001-02-02 2003-07-08 R. P. Scherer Technologies, Inc. Constricted neck blister pack and apparatus and method for making the same
AU2003233118B8 (en) 2002-05-07 2009-07-30 Ferring Bv Desmopressin in an orodispersible dosage form
DE602005009677D1 (de) 2004-03-22 2008-10-23 Solvay Pharm Gmbh Orale pharmazeutische zusammensetzungen von produkten mit lipase, insbesondere von pankreatin, mit tensiden
US8802145B2 (en) 2004-10-28 2014-08-12 Pantec Ag Highly porous, fast-disintegrating solid dosage form and its way of manufacturing comprising the preparation of a powder and a freezedrying step
WO2010025126A1 (en) 2008-08-26 2010-03-04 Cystic Fibrosis Foundation Therapeutics, Inc. Rapidly disintegrating tablets comprising lipase, amylase, and protease
WO2014166994A1 (en) 2013-04-09 2014-10-16 Danmarks Tekniske Universitet Nano-microdelivery systems for oral delivery of an active ingredient
CN104109662B (zh) 2014-06-23 2017-03-01 华中科技大学 一种固定化的洋葱伯克霍尔德菌脂肪酶及其制备方法
DE102015114857A1 (de) 2015-09-04 2017-03-09 Nordmark Arzneimittel Gmbh & Co. Kg Getränk, enthaltend eine pharmazeutische Zusammensetzung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1394607A (zh) * 2002-08-07 2003-02-05 王登之 治疗心绞痛的黄杨宁口腔崩解片及其制备方法
CN101068565A (zh) * 2004-10-14 2007-11-07 阿尔特斯制药公司 治疗胰腺功能不全的包含脂酶、蛋白酶和淀粉酶的组合物
DE102009006594A1 (de) * 2009-01-29 2010-08-05 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutisches Präparat
CN102231988A (zh) * 2009-01-29 2011-11-02 诺尔玛克药物有限责任及股份两合公司 细菌脂肪酶药物制剂

Also Published As

Publication number Publication date
EP3525769A1 (de) 2019-08-21
PL3525769T3 (pl) 2021-10-25
CA3055116C (en) 2023-07-11
WO2018158459A1 (de) 2018-09-07
US11464834B2 (en) 2022-10-11
EP3525769B1 (de) 2021-05-12
ES2880602T3 (es) 2021-11-25
CA3055116A1 (en) 2018-09-07
DE102017104472A1 (de) 2018-09-06
JP7208146B2 (ja) 2023-01-18
JP2020509052A (ja) 2020-03-26
US20200009232A1 (en) 2020-01-09
JP2022184994A (ja) 2022-12-13
CN110612098A (zh) 2019-12-24

Similar Documents

Publication Publication Date Title
CN110612098B (zh) 含有伯鲁酶的口腔分散片和由此生产的药物组合物
US20240245761A1 (en) Methods of treating celiac disease
KR101968457B1 (ko) 장용 코팅된 저 강도 췌장 리파제 제제
KR20030074625A (ko) 삶의 질을 개선하는 의약 및 식품 및 그 제조방법
EP2328609A1 (en) Rapidly disintegrating tablets comprising lipase, amylase, and protease
JP5970189B2 (ja) 医薬調製物
JP6568095B2 (ja) プロ酵素及び酵素の混合物を含む医薬組成物
NO326259B1 (no) Faste oralt-dispergerbare farmasoytiske formuleringer
JP7554807B2 (ja) 消化障害の予防および/または処置用の医薬組成物およびそれを製造する方法、並びにそれを含む医薬製品
US20230210782A1 (en) Non-porcine formulations and methods thereof
US20140356396A1 (en) Rotavirus preparations with excess calcium ions and high viscosities that ensure viability at elevated temperatures
US20060013807A1 (en) Rapidly disintegrating enzyme-containing solid oral dosage compositions
RU2276985C1 (ru) Фармацевтическая композиция для лечения заболеваний поджелудочной железы и расстройств пищеварения, связанных с заболеванием печени
JP2005239737A (ja) 生活の質を改善する新規医薬組成物の製法および用途
KR20250052666A (ko) 고용량 판크레아틴 직접타정용 약제학적 조성물, 및 이에 의해 제조된 장용성 정제
DE102017104501A1 (de) Pharmazeutische Zusammensetzung umfassend einen Träger und einen Überzug enthaltend wenigstens eine Lipase
WO2021202363A1 (en) Combined animal-derived and synthetically produced pancreatic enzyme replacement therapy
HK1204450B (en) Methods of treating celiac disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210819

Address after: German Uetersen

Applicant after: Normark Pharmaceutical Co.,Ltd.

Address before: German Uetersen

Applicant before: Nordmark Arzneimittel GmbH & Co.KG

GR01 Patent grant
GR01 Patent grant